Dr. William Schaffner of the Vanderbilt School of Medicine, addresses the latest polio outbreaks, and the importance of vaccinating children.
CNBC's Meg Tirrell reports the World Health Organization has confirmed about 262 cases of the MERS virus, of which 93 people have died. Dr. William Schaffner of the Vanderbilt School of Medicine, provides insight.
Apple is expanding to medical technology. The company is recruiting a team of medical executives and has offered hints of the iWatch and others.
AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.
The "Squawk on the Street" news team break down Merck's quarterly earnings beat and discuss the state of big pharma and taxes.
Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.
Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.
CNBC's Meg Tirrell reports a Cowen analyst is suggesting Allergan buy ADHD drug maker Shire. The FMHR traders, provide perspective.
CNBC's Meg Tirrell speaks with George Scangos, Biogen Idec CEO, about the drug maker's fight against MS and Alzheimer's. Scangos also comments on Valeant's bid for Alllergan.
Kevin Caron, Stifel Private Client Group market strategist, and Doug MacKay, Broadleaf Partners president & CIO, discuss signs of a tech bubble and share their investment strategies on hot technology stocks.
Record sales of a new hepatitis C drug pushed the first-quarter earnings of Gilead Sciences beyond expectations. The "Squawk on the Street" news team break down its quarterly beat.
CNBC's Meg Tirrell previews the earnings of biotech players Gilead and Amgen. Tirrell explains why investors will be focusing on Gilead's Sovaldi sales.
CNBC's Dominic Chu provides the big picture on some of the biggest players in biotech.
Discussing the pullback in biotech, with Paul Hickey, Bespoke Investment Group.
The FMHR traders debate the play on large cap versus small cap biotech stocks.
Discussing large cap versus small cap biotech stocks, and the hottest picks in the space, with Yaron Werber of Citi.
I think a lot of it had to do with pricing concerns over Gilead's Sovaldi, says Jason Kolbert, Maxim Group, sharing his thoughts on the future of the biotech sector and pending IPOs.
Ian Read, Pfizer CEO, discusses the pricing and affordability of drugs in the U.S. Read also weighs in on insurance coverage under the Affordable Care Act.
CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.
John Lechleiter, Chairman, President & CEO of Eli Lilly, discusses the company's growth plans as products come off patent and consumers move to generic drugs.